Quoin Pharmaceuticals Ltd (QNRX) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company...

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and...

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or...

Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Clinical site to be Opened in Saudi Arabia       Site Currently Treating Netherton Patients Who Are Eligible...

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or...

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or...

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing...

Form 424B3 - Prospectus [Rule 424(b)(3)]